Helén Tuvesson appointed as new Chief Scientific Officer at Active Biotech

16-Mar-2011 - Sweden

Dr. Helén Tuvesson takes up the post as Chief Scientific Officer within Active Biotech from April 1, 2011. Helén Tuvesson will be reporting to Tomas Leanderson, President & CEO.

Dr. Tuvesson has worked in the pharmaceutical industry for more than 20 years and has extensive experience in drug development, from the early preclinical stage up to late clinical development. Helén has been on different positions within Active Biotech since 1998, most recently as Head of the department of Preclinical Development. She has been a member of the R&D management for three years, and the recent year also in the senior management team at Active Biotech.

The appointment will strengthen Active Biotech's R&D capabilities going forward after the recent positive results obtained in the laquinimod and TASQ clinical studies.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances